---
title: "Hualan Vac: The freeze-dried type B influenza Haemophilus influenzae conjugate vaccine has obtained the drug clinical trial approval notice"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252806939.md"
description: "Hualan Vac recently received approval from the National Medical Products Administration to conduct clinical trials for the lyophilized type b Haemophilus influenzae conjugate vaccine. This vaccine aims to prevent invasive infections caused by type b Haemophilus influenzae, including meningitis and pneumonia. This approval marks the company's success in its vaccine research and development strategic layout, helping to consolidate its position in the domestic category II vaccine field and promote the sustainable development of its vaccine business"
datetime: "2025-08-13T07:59:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252806939.md)
  - [en](https://longbridge.com/en/news/252806939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252806939.md)
---

# Hualan Vac: The freeze-dried type B influenza Haemophilus influenzae conjugate vaccine has obtained the drug clinical trial approval notice

According to the Zhitong Finance APP, Hualan Vac (301207.SZ) announced that it recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the lyophilized Haemophilus influenzae type b conjugate vaccine (hereinafter referred to as "Hib vaccine"). After review, the Hib vaccine meets the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of invasive infections caused by Haemophilus influenzae type b (including meningitis, pneumonia, sepsis, cellulitis, arthritis, epiglottitis, etc.).

The approval of the "lyophilized Hib vaccine" marks a phased success in the company's product research and development strategy, which not only enriches the company's product layout but also represents an important step in achieving the company's multi-valent product development. This is beneficial for consolidating the company's industry position in the domestic category II vaccine field and supports the sustainable development of the company's vaccine business

### Related Stocks

- [301207.CN](https://longbridge.com/en/quote/301207.CN.md)

## Related News & Research

- [Sugar Prices Climb on Global Weather Concerns](https://longbridge.com/en/news/287261296.md)
- [Commentary: The football world will watch EPL’s streaming service debut in Singapore](https://longbridge.com/en/news/287277838.md)
- [The Intersection Between Technical Analysis and Commodity Futures Spreads](https://longbridge.com/en/news/287043412.md)
- [CEO.CA's Inside the Boardroom: How Viva Gold is Slashing Costs and De-Risking the Tonopah Gold Project in Nevada | VAUCF Stock News](https://longbridge.com/en/news/287236638.md)
- [How Leading Buy-Side Trading Desks Are Rethinking Execution Management](https://longbridge.com/en/news/286943904.md)